Authors
Makedonskaya O.G.1, Eikhler O.V.2, Zhiburt E.B.3
1 Mordoviya Republic Blood Transfusion Station, Saransk, Russia
2 Federal Medical Biological Agency, Moscow
3 Pirogov National Medical and Surgical Center, Moscow
Abstract
Plasma with antibodies to SARS-CoV-2 for passive immunotherapy is collected now from convalescents. We observed a cohort of 42 healthy people who received the Russian vaccine "Gam-COVID-Vac" (also known as Sputnik V), solution for intramuscular administration according to the prime-boost scheme: the introduction of component 1 was carried out on the 1st day, and component 2 - on the 21st day. Reciprocal titers of 2 antigen-specific antibodies (anti-S1 and anti-RBD) measured by two different ELISAs were monitored. We collected plasma (median – 600 ml) by apheresis on the days 21-30 from 7 donors and on the days 42-50 from 11 donors. SARS-CoV-2 S1-specific and RBD-specific IgGs were detected in 100% of our vaccinated plasma donors. All our donors were healthy and met the criteria for plasma donors. A week after donation, the median titers of both antibodies increased from 6400 to 12800. No adverse reactions were observed in donors. The prepared plasma met all generally accepted quality standards. Thus, with the introduction of vaccination against COVID-19, a new category of anti-SARS-CoV-2 plasma donors appears.
Keywords: blood, blood transfusion, plasma, vaccine, COVID-19, SARS-CoV-2, immunotherapy.
References
1. Shevchenko YuL, Karpov OE, Zhiburt EB. Blood transfusion: history and modernity (on the 100th anniversary of blood transfusion in Russia). Bulletin of Pirogov National Medical & Surgical Center. 2019;14(4):4–11.
2. Zhiburt EB. Our regulatory framework does not yet provide for the transfusion of any kind of immune plasma. Spravochnik zavedujushhego KDL. 2020;6:10–13.
3. Orlov AM, Popkova NG, Galimov ML. et al. Implementation of the collection and transfusion of anticovid plasma in the Sverdlovsk region. Transfuziologija. 2020;21(3):245–252.
4. Zhiburt EB. Plasma transfusion guidelines. Moscow: Meditsina; 2008.
5. Gil'mutdinov RG, Ishbuldina AM, Tjukina LJu, et al. Results of COVID-19 convalescent donors evaluation. Spravochnik zavedujushhego KDL. 2020;10:37–42.
6. Revishvili ASh, Shlyakhto EV, Zamyatin MN. et al. Features of the provision of emergency and urgent medical care to patients receiving direct oral anticoagulants. Consensus document of an interdisciplinary group of experts. Vestnik aritmologii. 2018;92: 59–72.
7. Zhiburt EB, Shestakov EA, Likhonin DA, Karavaev AV. Female plasma transfusion damages recipient's lungs. Bulletin of Pirogov National Medical & Surgical Center. 2011;6(2):109–111.
8. Zhiburt EB, Madzaev SR, Chemodanov IG. Complications of blood donation and blood transfusion. Moscow: Pirogov National Medical Surgical Center; 2019.
9. Zhiburt EB, Filina NG, Gubanova MN. Plasma virus inactivation. Bulletin of Pirogov National Medical & Surgical Center. 2007;2(1):105–110.
10. Kuznecov SI, Kudinova EV, Zhiburt EB. Blood collection in COVID-19 infection period. Menedzher zdravoohranenija. 2020;5:41–44.
11. Kuznecov SI, Aver'janov EG, Shestakov EA, Zhiburt EB. Digital monitoring of attitudes towards blood donation during the COVID-19 pandemic. Menedzher zdravoohranenija. 2020;6:50–55.
12. Kuznecov SI, Hamitov RG, Fomina VS. et al. RBC phenotype and COVID-19 infection. Spravochnik zavedujushhego KDL. 2020;9:16–22.
13. Tankaeva HS, Lachueva MK, Abdulaev IA. et al. Changes in the work of the blood service of Dagestan in the context of the COVID-19 pandemic. Transfuziologija. 2020;21(3):211–216.
14. Hamitov RG, Ajupova RF, Absaljamova LA, Zhiburt EB. Comparison of the results of different reagent kits for the detection of antibodies to SARS-CoV-2. Spravochnik zavedujushhego KDL. 2020;10:33–36.
15. Hamitov RG, Ajupova RF, Absaljamova LA, Zhiburt EB. Effect of pathogen inactivation on antibodies to SARS-CoV-2. Spravochnik zavedujushhego KDL. 2020;8:9–12.
16. Kuznecov SI, Kudinova EV, Zhiburt EB. Donor platelets collection in the context of the COVID-19 pandemic. Menedzher zdravoohranenija. 2020;9:43–46.
17. Investigational COVID-19 Convalescent Plasma. Guidance for Industry. [cited 2020 Nov 18].
18. Logunov DY, Dolzhikova VI, Zubkova VO, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887–897. doi: 10.1016/S0140-6736(20)31866-3.
